A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Studiedetails
Type carcinoma: | NSCLC met mutatie |
---|---|
Stadium: | IV |
Mutatie: | KRAS G12C |
Lijn: | Eerstelijns |
Site: | Erasmus MC |
Contactgegevens: | long.oncologie@erasmusmc.nl |
Website: | https://-/ |
Inclusiecriteria
- Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous) with
KRAS G12C mutation and known PD-L1 Tumor Proportion Score (TPS) score. - Unresectable or metastatic disease.
- Not a candidate for definitive therapy (e.g., chemoradiation for locally advanced
disease). - PD-L1 >50%
Exclusiecriteria
- Prior systemic treatment for locally advanced or metastatic NSCLC including
chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS
G12C mutation (e.g., AMG 510). - Radiation to the lung >30 Gy within 6 months prior to the first dose of study
treatment. - Active brain metastases. Patients are eligible if brain metastases are adequately
treated and patients are neurologically stable (except for residual signs or symptoms
related to the central nervous system [CNS] treatment) for at least 2 weeks prior to
the first dose of study treatment without the use of corticosteroids or are on a stable or
decreasing dose of ≤ 10 mg daily prednisone (or equivalent). - Carcinomatous meningitis.
Meer studies
Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:
TROPION-LUNG01
2de lijns | stadium IIIb-IV | AGA-positive
TEIPP
Stadium IV | 2de lijns
ORCHARD
EGFR | 2de lijn | stadium IV
MK-7684A
1ste lijn | Stadium IV
Mariposa
2de lijn | EGFR | stadium IIIIB - IV
KRYSTAL
Stadium IV | 2de lijn | KRAS G12C mutatie
ImmunoSABR
stadium IV - 1ste, 2de of 3de lijn
GENMAB
2de lijn - stadium IV
EVOKE
2de lijns | Stadium III/IV
Entrectinib
Stadium IIIB-IV | Eerstelijns | ROS1 mutation
Ensure
Eerstelijn | Fase I
CUP/EAP/DAP/DRUP
Lijst van verschillende programma's